Cabaletta Bio, Inc.
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
CABA | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2929 ARCH STREET, 19104 PHILADELPHIA
- Website:
- https://www.cabalettabio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cabaletta Bio, Inc. is a clinical-stage biotechnology company that discovers and develops engineered T cell therapies for patients with autoimmune diseases. The company's CABA® platform is used to create Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) therapies, which aim to provide deep, durable, and potentially curative responses. Its lead product candidate, CABA-201, is a CD19-CAR T cell therapy designed to deliver a one-time infusion that enables an "immune system reset." CABA-201 is being advanced in Phase 1/2 clinical trials for a broad range of autoimmune diseases, including systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cabaletta Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cabaletta Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cabaletta Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
